Amgen and AstraZeneca Report Phase 3 NAVIGATOR Results for Tezspire in Severe Asthma

Amgen and AstraZeneca today announced results from the Phase 3 NAVIGATOR trial evaluating Tezspire (tezepelumab) in patients with severe, uncontrolled asthma. The trial met its primary endpoint, demonstrating a significant reduction in annualized asthma exacerbation rates compared to placebo, with Tezspire showing a 70% reduction. Importantly, Tezspire showed efficacy across all severe asthma phenotypes, including patients with low eosinophil counts.